1985
DOI: 10.1523/jneurosci.05-06-01387.1985
|View full text |Cite
|
Sign up to set email alerts
|

Cholecystokinin-induced excitation in the substantia nigra: evidence for peripheral and central components

Abstract: Cholecystokinin (CCK), one of the most common brain peptides, coexists with dopamine (DA) in neurons of the medial substantia nigra (SN). CCK has been shown to excite these neurons following either direct iontophoretic or systemic administration suggesting that peripherally administered CCK may cross the blood brain barrier to act directly on nigral DA cells. However, biochemical evidence suggests that CCK does not cross the blood brain barrier, and several studies have shown that the behavioral and the satiet… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
18
0

Year Published

1988
1988
2011
2011

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 80 publications
(21 citation statements)
references
References 19 publications
3
18
0
Order By: Relevance
“…In support of our findings, peripherally administered caerulein has been reported to reduce endogenous dopamine release in the striatum (Hamamura et al 1989). Hommer et al (1985) have reported that CCK has an excitatory action on neural firing rate in the substantia nigra following peripheral administration. This opposite effect of caerulein and CCK on nigral dopaminergic neurons may be ascribed to the difference in drugs, experimental conditions and methodology.…”
Section: Discussionsupporting
confidence: 89%
See 1 more Smart Citation
“…In support of our findings, peripherally administered caerulein has been reported to reduce endogenous dopamine release in the striatum (Hamamura et al 1989). Hommer et al (1985) have reported that CCK has an excitatory action on neural firing rate in the substantia nigra following peripheral administration. This opposite effect of caerulein and CCK on nigral dopaminergic neurons may be ascribed to the difference in drugs, experimental conditions and methodology.…”
Section: Discussionsupporting
confidence: 89%
“…Peripheral administration of cholecystokinin evokes a number of behavioral effects, including satiety, decrease in exploratory behavior, sedation, and analgesia. Cholecystokinin octapeptide (CCK-8) decreases cerebral glucose metabolism in a characteristic pattern (Lucignani et al 1984) and has an excitatory action on neural firing rate in the mesencephalon following systemic administration (Skirboll et al 1981;Hommer et al 1985). Clinically, cholecystokinin (CCK) has been implicated in the etiology and treatment of schizophrenia.…”
mentioning
confidence: 99%
“…Portions of the DVC, however, have a "leaky" blood-brain barrier (2,5,25,28), and several groups have provided functional evidence of a possible hormonal action of CCK to affect vagal neurons directly. More specifically, Hommer and colleagues (35) showed that sys- temic administration of CCK activates a NTS-nigral pathway, which is interrupted by lesion of the medulla but not of vagal afferent pathways. Similarly, the short-term satiety effects of CCK are antagonized by the blood-brain barrier-permeant CCK-A antagonist devazepide, but not by A-70104, a selective CCK-A antagonist that does not cross the blood-brain barrier (52).…”
Section: Discussionmentioning
confidence: 99%
“…These morphological characteristics raise the possibility that NTS neuronal activity can be modulated by circulating molecules, including CCK. In fact, there is functional evidence that CCK can cross the BBB to activate a solitarius-nigral pathway (27), to phosphorylate CCK-A receptors in the DVC (65) and to induce short-term satiety (10).…”
Section: Discussionmentioning
confidence: 99%